at CNBC.com (Fri, 9:07AM)
Actavis, which is being acquired by Watson Pharmaceuticals (WPI +0.2%), says that on June 29 it received tentative approval from the FDA for Guanfacine Extended-Release Tablets, a generic equivalent to Shire's (SHPGY -2.5%) Intuniv. Intuniv had US sales of approximately $342M for the 12 months ending March 31.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Tue, 6:00PM)
at Investor's Business Daily (Jan 22, 2015)
at Zacks.com (Jan 20, 2015)
at CNBC.com (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs